Michael Pollak
Molecular Biology · 2000–2014
A researcher in the Science corpus: 11 papers; trusts 18 researchers and is trusted by 17 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 154 citations into it; #2,766 of 17,773 by trust here, #3,138 by citations
- Endocrinology, Diabetes and Metabolism — 56 citations into it; #39 of 623 by trust here, #110 by citations
- Surgery — 49 citations into it
- Oncology — 48 citations into it
- Cancer Research — 38 citations into it
- Epidemiology — 15 citations into it
Whom Michael Pollak trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
- S. Firth
- R. Shaw
- E. Calle
- Guido Kroemer
- D. Hardie
- M. V. Vander Heiden
- Yang Wei-we
- S. Suissa
- E. Schernhammer
- V. Longo
Who trusts Michael Pollak overall
- J. P. Thiery
- Edward L. Giovannucci
- Prashanth Rawla
- H. Acloque
- M. V. Vander Heiden
- D. Shackelford
- David M. Harlan
- S. Bose
- M. Khandekar
- R. Huang
Papers from Michael Pollak's perspective
Ordered by how strongly the researchers Michael Pollak trusts endorse each paper. Same corpus, a different order for every researcher.
- TSC2 mediates cellular energy response to control cell growth and survival. (Cell)
- Metformin and reduced risk of cancer in diabetic patients (British medical journal)
- Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin (Diabetes Care)
- AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. (Cell Metabolism)
- TOR signaling in growth and metabolism. (Cell)
- The tor pathway: a target for cancer therapy (Nature Reviews. Cancer)
- The regulation of AMP-activated protein kinase by phosphorylation. (Biochemical Journal)
- The LKB1 tumor suppressor negatively regulates mTOR signaling. (Cancer Cell)
- Upstream and downstream of mTOR. (Genes & Development)
- Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. (Genes & Development)
Their papers
- Insulin and insulin-like growth factor signalling in neoplasia (2008) — 2,106 citations
- Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. (2007) — 954 citations
- Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. (2006) — 1,090 citations
- Metformin improves healthspan and lifespan in mice (2013) — 1,361 citations
- Insulin-like growth factors and neoplasia (2004) — 1,533 citations
- Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). (2001) — 937 citations
- Diabetes and Cancer (2010) — 1,959 citations
- The insulin and insulin-like growth factor receptor family in neoplasia: an update (2012) — 1,090 citations
- Metformin: from mechanisms of action to therapies. (2014) — 1,386 citations
- mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. (2013) — 787 citations
- Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. (2000) — 1,012 citations